Avexima Ranks Among Leading Pharmaceutical Companies According to CURSOR¹

The pharmaceutical company Avexima has made it into the top of two ratings compiled by CURSOR analysts: the rating of the largest drug manufacturers and the rating of major full-cycle Russian pharmaceutical manufacturers within the Vital and Essential Drugs List (VEDL).

In the rating of domestic drug manufacturers, Avexima ranks among the top 15*. The company's portfolio comprises 116 International Nonproprietary Names (INN) and 237 valid marketing authorizations. By the number of INNs in solid dosage forms, Avexima ranks 8th.

In the rating of full-cycle manufacturers within the VEDL, the company secured a position in the top-20. The company's portfolio includes 21 INNs with domestically produced active pharmaceutical ingredients (APIs), and the share of in-house manufactured APIs in its full-cycle drug portfolio amounts to 62%.

«The business strategy of Avexima for the near future involves a further increase in the number of INNs and marketing authorizations to strengthen its position in the Russian pharmaceutical market», stated Yuri Karpenko, Commercial Director of JSC Avexima.

*By the number of INNs

¹ https://cursor-is.ru., accessed September 30, 2025